Reformulation on Zantrene seems to be a massive advantage for...

Reformulation on Zantrene seems to be a massive advantage for patient comfort.

Announcement: Race Initiates Strategic Zantrene Formulation Collaboration with the University of Wollongong – Race Oncology

Current administration must be undertaken in hospital setting. The hope is to reformulate to create peripheral IV administration in outpatient setting, or, orally potentially at home - whilst maintaining efficacy and improving patient treatment.

Questions I has asked myself:

1. What is the general development timeline of reformulations
2. Have there been any Zantrene reformulation attempts in the past
3. What are some of the barriers to perhipheral IV administration reformulation
4. Will oral reformulation be possible and is there any loss of efficacy

Noticed that the Rotham papers suggest Zantrene was inactive orally. Assuming tech from 1970 to 1980 has improved drastically. Hopefully there are some work arounds, just have to keep digging.

Source: Rothman papers the-rediscovery-of-bisantrene-a-review-of-the-literature-ijcrt-17-015.pdf (opastonline.com)